• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Increased detection of high-risk prostate cancer with targeted biopsy technique

byPriyanka Vedak
January 28, 2015
in Chronic Disease, Oncology, Urology
Reading Time: 3 mins read
Long-term active surveillance may be safe in low-risk prostate cancer
Share on FacebookShare on Twitter

1. Increased rates of high-risk prostate cancer was detected among individuals with suspected prostate cancer using a targeted technique for prostate biopsy, versus the current standard technique.

2. The targeted technique resulted in lower detection of low-risk prostate cancer than that detected using the current standard technique.

Evidence Rating Level: 2 (Good)          

Study Rundown: The standard biopsy technique currently utilized to detect prostate cancer involves random sampling of the entire organ rather than a targeted image-guided process. This study aimed to compare the efficacy of the current standard biopsy technique with the efficacy of targeted biopsy technique involving multiparametric magnetic resonance imaging (MP-MRI) and the efficacy achieved using both techniques combined. The study prospectively enrolled 1003 men who demonstrated at least one abnormal prostate lesion detected on MP-MRI following either an elevated prostate specific antigen (PSA) or abnormal prostate exam. Patient subsequently received a targeted biopsy using the MP-MRI findings and a standard biopsy performed by a physician who was blinded to the MP-MRI findings. Analysis of the collected pathological samples revealed increased detection of high-risk prostate cancer using the targeted technique, but decreased detection of low-risk prostate cancer. Minimal benefit was achieved by using both techniques together. While these promising findings indicate that targeted biopsy may improve detection of high-risk prostate cancer, this study is preliminary in nature. Additional studies are required to assess the impact of this biopsy technique on other clinical outcomes including survival prior to widespread implementation, particularly given the additional costs associated with the targeted technique.

Click to read the study, published today in JAMA

Click to read an accompanying editorial, published today in JAMA

RELATED REPORTS

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

Stockholm3 outperforms PSA for detecting significant prostate cancer 

Pfizer’s Talzenna combo significantly delays prostate cancer progression

Relevant Reading: Utility of Multiparametric Magnetic Resonance Imaging Suspicion Levels for Detecting Prostate Cancer

In-Depth [prospective cohort]: This study enrolled 1003 patients at the National Cancer Institute in Bethesda, Maryland who demonstrated at least one abnormal prostate lesion detected on MP-MRI following either an elevated prostate specific antigen (PSA) or abnormal prostate exam. All patients underwent a targeted biopsy and standard technique biopsy and pathological samples were graded for risk level using the Gleason scored. While 461 patients were diagnosed with prostate cancer using targeted biopsy and 469 patients using standard biopsy, 173 high-risk and 213 low-risk cases were diagnosed with the targeted technique versus 122 high-risk and 258 low-risk cases with the standard biopsy. This resulted in targeted technique detecting 30% more high-risk cases and 17% fewer low-risk cases than standard technique. When the pathological yield of adding a standard biopsy to targeted biopsy was assessed, it was determined that 200 additional men would have to receive both biopsies in order to detect 1 additional case of high-risk cancer.

More from this author: Entecavir more effective than lamivudine in preventing HBV reactivation, No change in health or education outcomes following implementation of duty-hour restrictions, Full-day preschool programs linked to improved overall student performance , β-blockers linked to improved survival in preserved ejection fraction heart failure, Adding sargramostim to ipilimumab may improve survival in advanced melanoma

Image: CC/Wiki

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. No article should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2 Minute Medicine, Inc.

Tags: prostate cancer
Previous Post

Cancer cell mechanical behavior a target for drug treatment [PreClinical]

Next Post

Age may not impact residential status after abdominal surgery

RelatedReports

Radiation plus hormone therapy may improve prostate cancer survival
Chronic Disease

Enzalutamide (Xtandi) and abiraterone (Zytiga) may have similar effectiveness in metastatic castration-sensitive prostate cancer

July 22, 2026
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial
Oncology

Stockholm3 outperforms PSA for detecting significant prostate cancer 

June 22, 2026
Radiation plus hormone therapy may improve prostate cancer survival
Oncology

Pfizer’s Talzenna combo significantly delays prostate cancer progression

April 9, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Endocrinology

2 Minute Medicine: Pharma Roundup – Pfizer’s Talzenna delays prostate cancer progression, apixaban lowers VTE bleeding risk, Lilly’s retatrutide hits Phase III metabolic targets, and FDA warns Novo Nordisk over safety reporting violations [March 2026]

March 30, 2026
Next Post
Age may not impact residential status after abdominal surgery

Age may not impact residential status after abdominal surgery

High incidence of bilateral lower extremity inflammatory lymphedema in air force trainees

High incidence of bilateral lower extremity inflammatory lymphedema in air force trainees

Resident involvement may not increase postoperative complications in neurosurgery

Resident involvement may not increase postoperative complications in neurosurgery

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • N-methylaniline exposure identified as likely cause of methemoglobinemia during maritime migration
  • Video mental health care may have clinical advantages versus phone or in-person visits
  • Higher maternal body mass index is associated with increased risk of cardiovascular disease in offspring
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.